Suppr超能文献

恩诺沙星(拜有利)有效治疗细胞系中的支原体污染

Effective treatment of mycoplasma contamination in cell lines with enrofloxacin (Baytril).

作者信息

Fleckenstein E, Uphoff C C, Drexler H G

机构信息

Department of Human and Animal Cell Cultures, DSM-German Collection of Microorganisms and Cell Cultures, Braunschweig.

出版信息

Leukemia. 1994 Aug;8(8):1424-34.

PMID:7520103
Abstract

Continuous cell lines are frequently contaminated with microorganisms, mycoplasmas being the most prominent and cumbersome. In our experience, of the 300 cell lines examined more than one third was infected with mycoplasmas. Mycoplasma contamination can affect virtually every parameter and functional activity of a cultured cell. An alternative to the recommended disposal of infected cultures is an attempt to eliminate the contaminants. Adding antibiotics with strong activity against mycoplasmas to the culture medium is a simple, inexpensive and efficient decontamination method. Here, we studied the effectiveness of the new antibiotic enrofloxacin (Baytril) developed specifically for use against mycoplasmas. Baytril is a new synthetic agent from the group of quinolone derivatives that are DNA gyrase inhibitors. Thirty-two chronically infected cell lines (27 human leukemia-lymphoma cell lines) were treated with Baytril in a prospective study in direct comparison with three other well-established anti-mycoplasma regimens, the antibiotics BM-Cyclin, Ciprobay and MRA (Mycoplasma Removal Agent). Mycoplasmas were detected by DNA staining, agar colony growth, DNA-RNA hybridization, polymerase chain reaction, and monoclonal antibody staining. Treatment with Baytril eliminated the contaminants in 30/32 cultures (94%). The cure rates for Ciprobay, BM-Cyclin and MRA were 91%, 81%, and 75%, respectively. The IC50 values of Baytril for cell lines varied over a wide range depending on the type of hematopoietic cell lineage with T- and B-cell lines being more sensitive targets. Baytril-treated cell lines remained mycoplasma-negative over a 12-week antibiotic-free culture period. Low levels of mycoplasma infection were shown not to persist by repeat testing after growth without antibiotics. A retrospective analysis of anti-mycoplasma treatments with BM-Cyclin, Ciprobay, MRA or Baytril showed that 265/351 cultures (75%) were immediately cured of mycoplasma; however, all of the remaining, mycoplasma-positive cultures harboring mycoplasms resistant to the first antibiotic could be cleaned up by a second round with a different antibiotic. Baytril is an efficient anti-mycoplasma antibiotic and based on its high cure rate might be the treatment of first choice.

摘要

连续细胞系经常受到微生物污染,其中支原体最为常见且难以处理。根据我们的经验,在检测的300个细胞系中,超过三分之一感染了支原体。支原体污染实际上会影响培养细胞的每个参数和功能活性。除了建议处理受感染的培养物外,另一种方法是尝试消除污染物。向培养基中添加对支原体具有强效活性的抗生素是一种简单、廉价且有效的去污方法。在此,我们研究了专门开发用于对抗支原体的新型抗生素恩诺沙星(拜有利)的有效性。拜有利是喹诺酮衍生物组中的一种新型合成剂,属于DNA回旋酶抑制剂。在一项前瞻性研究中,用拜有利对32个慢性感染的细胞系(27个人类白血病 - 淋巴瘤细胞系)进行处理,并与其他三种成熟的抗支原体方案(抗生素BM - 环素、环丙沙星和MRA(支原体清除剂))进行直接比较。通过DNA染色、琼脂菌落生长、DNA - RNA杂交、聚合酶链反应和单克隆抗体染色检测支原体。用拜有利处理使30/32个培养物(94%)中的污染物消除。环丙沙星、BM - 环素和MRA的治愈率分别为91%、81%和75%。拜有利对细胞系的IC50值因造血细胞系类型而异,T细胞系和B细胞系是更敏感的靶点。经拜有利处理的细胞系在12周无抗生素培养期内保持支原体阴性。在无抗生素生长后通过重复检测表明,低水平的支原体感染不会持续存在。对用BM - 环素、环丙沙星、MRA或拜有利进行的抗支原体治疗的回顾性分析表明,265/351个培养物(75%)的支原体立即被清除;然而,所有剩余的、携带对第一种抗生素耐药的支原体的支原体阳性培养物,通过第二轮使用不同的抗生素都可以清理干净。拜有利是一种有效的抗支原体抗生素,基于其高治愈率,可能是首选治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验